Literature DB >> 16629940

Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases.

Y Miyake1, Y Iwasaki, R Terada, T Onishi, R Okamoto, N Sakai, K Sakaguchi, Y Shiratori.   

Abstract

BACKGROUND: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. AIM: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis.
METHODS: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed.
RESULTS: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period.
CONCLUSIONS: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered for liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16629940     DOI: 10.1111/j.1365-2036.2006.02894.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Clinicopathological features of severe and fulminant forms of autoimmune hepatitis.

Authors:  Shin Yasui; Keiichi Fujiwara; Yutaka Yonemitsu; Shigeto Oda; Masayuki Nakano; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2010-09-07       Impact factor: 7.527

2.  A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody.

Authors:  Keiichi Fujiwara; Katsushi Seza; Yoshihiro Fukuda; Masayuki Nakano; Osamu Yokosuka
Journal:  Clin J Gastroenterol       Date:  2013-09-08

Review 3.  Management of Difficult Cases of Autoimmune Hepatitis.

Authors:  Craig Lammert; Veronica M Loy; Kiyoko Oshima; Samer Gawrieh
Journal:  Curr Gastroenterol Rep       Date:  2016-02

Review 4.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 5.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

6.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

7.  Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure.

Authors:  Bing Zhu; Shao-Li You; Zhi-Hong Wan; Hong-Ling Liu; Yi-Hui Rong; Hong Zang; Shao-Jie Xin
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 8.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 9.  [Autoimmune liver diseases].

Authors:  S Lüth; C Weiler-Normann; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2009-03       Impact factor: 0.743

10.  Clinical heterogeneity in autoimmune acute liver failure.

Authors:  Norberto C Chavez-Tapia; Julio Martinez-Salgado; Julio Granados; Misael Uribe; Felix I Tellez-Avila
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.